International Union of Basic and Clinical Pharmacology xxx: Applying an objective evaluation to the status of Class A orphan G protein-coupled receptors

In this review, we, on behalf of the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), describe criteria for assessing the evidence for pairing receptors and endogenous/physiological ligands for formal receptor deorphanization.This process is illustrated through consideration of the Class A G protein-coupled receptors (GPCR) not yet formally paired with an endogenous/physiological ligand by NC-IUPHAR.Of the 67 orphan Class A GPCR considered, twenty-five Class A GPCRs have no identified endogenous agonists, although five (GPR21, GPR27, GPR52, GPR85 and GPR88) have synthetic ligands that have the potential to be used as tools for uncovering physiological roles and further pharmacological properties of these receptors.Surprisingly, six orphan GPCRs (GPR135, GPR152, GPR153, MRGPRF, MRGPRG and MRGPRX3) have no clear pharmacology or phenotype reported following genetic disruption.Thirty-two orphan GPCRs have been paired with at least one endogenous agonist (mainly lipids and their derivatives, peptides and other metabolites) but further characterization is required from the scientific community to validate these results.We identify 10 orphan Class A orphan GPCRs for which there are plausible grounds for considering deorphanization: GPR4 (protons), GPR15 (GPR15L), GPR31 (12S-HETE), GPR39 (zinc divalent ions, Zn 2+ ), GPR65 (protons), GPR68 (protons), GPR132 (9-HODE), GPR183 (7,25-dihydroxycholesterol), MRGPRD (-alanine) and MRGPRX1 (bovine adrenal medulla peptide, BAM-8-22).The issue of nomenclature of these 10 GPCRs will be considered by further subcommittees of NC-IUPHAR.We hope this review will prompt further investigations of these members of the currently most widely clinically exploited protein superfamily.Significance statement (1-2 sentences; 80-word maximum -currently 67)The use of systematic, rational nomenclature for drug targets provides a framework to ensure consistent identification and rapid recognition.Given that G protein-coupled receptors have fundamental physiological roles and are widespread targets of drugs in current clinical use, we hope the target summary and deorphanization criteria provided here will prompt renewed efforts to investigate these orphan receptors as regulators of physiology and opportunities for future therapeutic exploitation.

Authors

Institutions

Publication Details

Journal
Pharmacological Reviews
Published
2026-05-01
DOI
https://doi.org/10.1016/j.pharmr.2026.100141
Primary Topic
Receptor Mechanisms and Signaling
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

International Union of Basic and Clinical Pharmacology xxx: Applying an objective evaluation to the status of Class A orphan G protein-coupled receptors

Rick R. Neubig, K.A. Bennett, Elena Faccenda, Christopher J. Langmead et al.
Pharmacological Reviews
Receptor Mechanisms and Signaling
article

International Union of Basic and Clinical Pharmacology xxx: Applying an objective evaluation to the status of Class A orphan G protein-coupled receptors

Rick R. Neubig, K.A. Bennett, Elena Faccenda, Christopher J. Langmead, Michelle Glass, Anthony P. Davenport, Gunnar Schulte, Kirill A. Martemyanov, Simon D Harding, Nicola J. Smith, S P H Alexander, Eamonn Kelly, Julien Hanson, Huixian Wu, Paul A. Insel, Stefan Offermanns, Mette M. Rosenkilde, David E. Gloriam, Andrew W. Brown
article en

Abstract

In this review, we, on behalf of the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), describe criteria for assessing the evidence for pairing receptors and endogenous/physiological ligands for formal receptor deorphanization.This process is illustrated through consideration of the Class A G protein-coupled receptors (GPCR) not yet formally paired with an endogenous/physiological ligand by NC-IUPHAR.Of the 67 orphan Class A GPCR considered, twenty-five Class A GPCRs have no identified endogenous agonists, although five (GPR21, GPR27, GPR52, GPR85 and GPR88) have synthetic ligands that have the potential to be used as tools for uncovering physiological roles and further pharmacological properties of these receptors.Surprisingly, six orphan GPCRs (GPR135, GPR152, GPR153, MRGPRF, MRGPRG and MRGPRX3) have no clear pharmacology or phenotype reported following genetic disruption.Thirty-two orphan GPCRs have been paired with at least one endogenous agonist (mainly lipids and their derivatives, peptides and other metabolites) but further characterization is required from the scientific community to validate these results.We identify 10 orphan Class A orphan GPCRs for which there are plausible grounds for considering deorphanization: GPR4 (protons), GPR15 (GPR15L), GPR31 (12S-HETE), GPR39 (zinc divalent ions, Zn 2+ ), GPR65 (protons), GPR68 (protons), GPR132 (9-HODE), GPR183 (7,25-dihydroxycholesterol), MRGPRD (-alanine) and MRGPRX1 (bovine adrenal medulla peptide, BAM-8-22).The issue of nomenclature of these 10 GPCRs will be considered by further subcommittees of NC-IUPHAR.We hope this review will prompt further investigations of these members of the currently most widely clinically exploited protein superfamily.Significance statement (1-2 sentences; 80-word maximum -currently 67)The use of systematic, rational nomenclature for drug targets provides a framework to ensure consistent identification and rapid recognition.Given that G protein-coupled receptors have fundamental physiological roles and are widespread targets of drugs in current clinical use, we hope the target summary and deorphanization criteria provided here will prompt renewed efforts to investigate these orphan receptors as regulators of physiology and opportunities for future therapeutic exploitation.

Pharmacological Reviews
Goethe University Frankfurt (DE), Scripps Research Institute (US), University of Copenhagen (DK), The University of Sydney (AU), University of Hertfordshire (GB), University of Nottingham (GB), University of Liège (BE), Pfizer (United States) (US), Discovery Institute (US), Karolinska Institutet (SE), University of Bristol (GB), University of California San Diego (US), Max Planck Institute for Heart and Lung Research (DE), Granta Design (United Kingdom) (GB), Addenbrooke's Hospital (GB), University of Otago (NZ), Michigan State University (US), University of Edinburgh (GB)
Fonds De La Recherche Scientifique - FNRS, Karolinska Institutet, Vetenskapsrådet
Partnerships for the goals
Openalex Percentile: Top 8%
Receptor Mechanisms and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.